Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
specificThe reemergence of diffuse midline glioma, H3 K27M mutant, after a period of remission.
5
Centers
5
Active Trials
—
Cancer Funding
Top Centers for Recurrent Diffuse Midline Glioma, H3 K27M-Mutant(5)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 60.0 |
| 2 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 60.0 |
| 3 | University of Illinois Cancer CenterChicago, IL Active Research Program | 60.0 |
| 4 | Boston University Cancer CenterBoston, MA Active Research Program | 60.0 |
| 5 | Cancer Center at IllinoisUrbana, IL Active Research Program | 60.0 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →